Veozah (Fezolinetant) in Your 20s: What Women Need to Know

Why a Woman in Her 20s Might Be Asking About Veozah

Hot flashes are not a menopause-only symptom. That is the short answer to why you might be here.

If you are in your 20s and experiencing sudden waves of heat, drenching night sweats, or flushing, you are right to take those symptoms seriously. But vasomotor symptoms in a woman under 30 almost always point to something other than natural menopause, and the treatment path is meaningfully different.

Veozah (fezolinetant) is a neurokinin 3 (NK3) receptor antagonist that works by blocking the hypothalamic thermoregulatory pathway that triggers hot flashes. The FDA approved fezolinetant in May 2023 specifically for moderate-to-severe vasomotor symptoms associated with menopause. That approval language matters. It was studied in peri- and postmenopausal women, not in women in their 20s with functioning ovaries.

This article will walk you through what fezolinetant does, why it probably is not the right fit for most women in their 20s, what conditions might actually be driving your symptoms, and what to ask your clinician instead.

How Fezolinetant Works: The NK3 Pathway Explained

Fezolinetant targets a very specific circuit in the brain. The short version: estrogen normally keeps a group of hypothalamic neurons (kisspeptin-neurokinin B-dynorphin, or KNDy neurons) quiet. When estrogen drops, as it does in menopause, those neurons become overactive and flood the NK3 receptor, which tells the body to release heat. Hot flash triggered.

Research published in Menopause confirmed that fezolinetant 45 mg once daily reduced the frequency of moderate-to-severe hot flashes by approximately 60% compared to placebo at week 12 in postmenopausal women enrolled in the SKYLIGHT 1 and SKYLIGHT 2 trials.

What This Means If You Still Have Estrogen

Here is where age becomes critical. If you are in your 20s and your ovaries are functioning normally, your estrogen levels are not depleted in the same way they are in menopause. The NK3 pathway is not the primary driver of vasomotor symptoms in premenopausal women. Blocking NK3 receptors in that context is, at best, untested and, at worst, potentially new to the reproductive hormone axis.

Neurokinin B is a key regulator of the gonadotropin-releasing hormone (GnRH) pulse generator, which means it directly controls ovarian function and the menstrual cycle. Blocking NK3 receptors in a premenopausal woman could theoretically suppress LH pulsatility and disrupt ovulation, though no long-term human fertility data in premenopausal women exist for fezolinetant specifically.

The SKYLIGHT Trial Enrollment Age

The SKYLIGHT 1 trial enrolled women aged 40 to 65 who were in natural or surgically induced menopause. No women in their 20s were included. Extrapolating the safety and efficacy data to a 24-year-old with regular periods is not supported by any published evidence.

Hot Flashes in Your 20s: What Is Actually Going On

If you are in your 20s and having genuine vasomotor symptoms, get a thorough workup before accepting any diagnosis or treatment. Several conditions can produce hot flashes, night sweats, and flushing in young women.

Primary Ovarian Insufficiency

Primary ovarian insufficiency (POI) affects approximately 1% of women under age 40, including women in their 20s. In POI, the ovaries stop functioning normally before age 40, leading to low estrogen, elevated FSH, irregular or absent periods, and vasomotor symptoms that genuinely resemble those of natural menopause. A woman with POI does have depleted estrogen, and her NK3 pathway may behave similarly to that of a postmenopausal woman.

Even so, Veozah is not the standard-of-care treatment for POI. ACOG and the Menopause Society recommend hormone therapy as the primary treatment for women with POI who do not have contraindications, because estrogen replacement in POI addresses bone loss, cardiovascular risk, and genitourinary health in ways that a symptom-focused NK3 blocker does not.

PCOS and Hormonal Fluctuations

Polycystic ovary syndrome affects roughly 8 to 13% of women of reproductive age. The Rotterdam criteria define PCOS by at least two of three features: irregular ovulation, clinical or biochemical hyperandrogenism, and polycystic ovarian morphology. Women with PCOS can experience hormonal swings that sometimes produce flushing, though true vasomotor symptoms from PCOS are less well characterized than those of menopause or POI. If you have PCOS and are experiencing hot flashes, the treatment target is the underlying hormonal dysregulation, not the NK3 pathway.

Thyroid Disease

Thyrotoxicosis and hyperthyroidism are well-recognized causes of heat intolerance, sweating, and flushing in young women. A simple TSH test will rule this in or out.

Surgical or Iatrogenic Menopause

If you have had both ovaries removed (bilateral oophorectomy) for any reason, including severe endometriosis, you will experience surgical menopause regardless of age. Surgical menopause in your 20s is abrupt and often produces more severe vasomotor symptoms than natural menopause. In this situation, Veozah is at least on-label if you are postmenopausal by clinical definition. Even then, most guidelines prioritize hormone therapy for young women post-oophorectomy because of the bone and cardiovascular protection it provides, and Veozah would be reserved for women who cannot or choose not to use hormones.

Medication-Induced Vasomotor Symptoms

Certain medications trigger hot flashes in young women: tamoxifen (used in BRCA-positive women or those with early breast cancer), GnRH agonists (used to treat endometriosis or fibroids), and aromatase inhibitors. If you are on one of these drugs, your clinician may consider off-label options, but again, fezolinetant has not been studied in this population.

Who Veozah Is Right For (and Not Right For), by Life Stage

This section addresses the key decision framework directly, organized by where you are in your reproductive life.

Women in Their 20s With Regular Cycles: Not Indicated

If you have regular menstrual cycles and no underlying condition causing estrogen deficiency, Veozah is not indicated. Your symptoms need a diagnosis first. Treating hot flashes in a young cycling woman with an NK3 blocker that has no premenopausal safety data is not evidence-based care.

Women in Their 20s With POI: Rarely the Right Choice

Even with confirmed POI, hormone therapy is the preferred treatment for vasomotor symptoms and carries additional protective benefits for bone density and cardiovascular health that fezolinetant does not provide. Veozah might enter the picture only if hormone therapy is contraindicated (for example, a history of certain hormone-sensitive cancers) and symptoms are significantly affecting quality of life, but this would be a highly individualized, off-label decision made with a specialist.

Women in Their 20s Post-Oophorectomy: On-Label But Second-Line

If you are in your 20s and surgically menopausal, fezolinetant is technically on-label. The Menopause Society's 2023 position statement notes that non-hormonal options including NK3 antagonists are appropriate for women who cannot use or choose not to use hormone therapy. This applies to you only if HT is genuinely contraindicated or declined after a thorough informed-consent conversation.

Women in Their 20s Who Are Trying to Conceive: Contraindicated

Fezolinetant is contraindicated in women who are pregnant or trying to conceive. Read the pregnancy and lactation section below carefully.

Pregnancy, Lactation, and Contraception: What You Must Know

This section is required reading if you are of reproductive age.

Pregnancy Risk: Animal Data Show Fetal Harm

The FDA prescribing information for fezolinetant states that animal reproduction studies showed fetal harm at doses lower than the human therapeutic dose. Specifically, embryo-fetal toxicity was observed in rat and rabbit studies. There are no adequate and well-controlled studies in pregnant women, which means the human pregnancy risk is unknown but animal data raise a significant concern.

Fezolinetant does not have a legacy FDA pregnancy category letter (the A/B/C/D/X system was phased out), but based on animal data it would functionally correspond to Category D at minimum. If you are pregnant or planning a pregnancy, do not take Veozah.

Contraception Requirement

Because of the fetal harm signal, the fezolinetant prescribing label requires that women of reproductive potential use effective contraception during treatment. This is not optional guidance. If you are in your 20s and sexually active, this requirement alone should be a central part of any prescribing conversation.

Effective contraception means a method with a typical-use failure rate below 10% per year. Combined hormonal contraceptives, progestin-only pills, the hormonal IUD, the copper IUD, the implant, and consistent condom use with a highly effective second method all qualify. Discuss your contraception status explicitly with your clinician before starting fezolinetant.

Lactation: Unknown Transfer, Breastfeeding Not Recommended

No human lactation data exist for fezolinetant. The prescribing information advises that because fezolinetant or its metabolites may be excreted in human milk, and because of the potential for serious adverse reactions in a breastfed infant, breastfeeding is not recommended during treatment. Given that the drug works on a neuroendocrine pathway, the theoretical risk to infant development cannot be dismissed.

If you are postpartum and breastfeeding and experiencing vasomotor symptoms, which are common in the postpartum period due to progesterone and estrogen withdrawal, discuss safer options with your provider. Postpartum hot flashes typically resolve as prolactin normalizes and ovarian function returns. They do not require an NK3 blocker.

Dosing and Liver Safety Monitoring

The standard fezolinetant dose is 45 mg orally once daily, taken with or without food. No dose adjustment exists for younger women specifically, because younger women were not studied.

Hepatotoxicity: The Monitoring Schedule You Cannot Skip

A meaningful safety finding from the SKYLIGHT trials was a signal for drug-induced liver injury. In the SKYLIGHT 4 long-term safety trial, approximately 2.3% of women taking fezolinetant 45 mg experienced ALT or AST elevations greater than three times the upper limit of normal, compared to 0.7% in the placebo group. Three cases met criteria for serious hepatocellular injury.

Because of this, the FDA requires liver function testing (ALT, AST, total bilirubin) at:

• Baseline (before starting)
• 3 months after starting
• 6 months after starting

Fezolinetant should be discontinued if ALT or AST rises above three times the upper limit of normal. This monitoring requirement applies to any woman taking Veozah, regardless of age.

Drug Interactions

Fezolinetant is metabolized by CYP1A2. Strong CYP1A2 inhibitors such as fluvoxamine substantially increase fezolinetant plasma concentrations and are contraindicated with concurrent use. Women in their 20s who smoke should know that tobacco is a CYP1A2 inducer and may reduce drug exposure, though this has not been studied in clinical practice for fezolinetant specifically.

What the Evidence Gap Means for You

Women in their 20s have been effectively invisible in fezolinetant research. This is not unusual. Women of reproductive age, particularly those who might become pregnant, have been excluded from drug trials for decades, leaving clinicians to extrapolate adult data downward and postmenopausal data sideways.

The SKYLIGHT trial program enrolled women aged 40 to 65 in natural or surgical menopause. No premenopausal women were included. The NK3 pathway in a cycling woman with normal estrogen behaves differently from the same pathway in a postmenopausal woman, and no published trial has characterized what blocking it does to the reproductive hormone axis in a 24- or 28-year-old.

This is not a reason to panic if you have taken fezolinetant briefly without knowing this. It is a reason to have an honest conversation with your clinician about whether the evidence supports continuing it, and to be skeptical of any provider who prescribes it to a young cycling woman without a clear diagnostic rationale.

Rachel Goldberg, MD, WomanRx editorial board OB-GYN and reproductive endocrinologist, puts it this way: "When a woman in her 20s comes to me with hot flashes, my first job is a diagnosis, not a prescription. Fezolinetant is a sophisticated drug designed for a specific hormonal context. Prescribing it to a young woman without first ruling out POI, thyroid disease, or a medication effect is skipping the most important clinical step."

Alternatives to Consider If You Are in Your 20s With Vasomotor Symptoms

If fezolinetant is not the right fit, what might be?

If you have confirmed POI: Systemic estrogen therapy plus a progestogen (if you have a uterus) is the ACOG-recommended standard of care, continued at least until the average age of natural menopause (around 51).

If you have PCOS with hormonal instability: Combined oral contraceptives remain a first-line option for cycle regulation and symptom management, with the specific formulation chosen based on your androgen levels and metabolic profile.

If you have medication-induced vasomotor symptoms (tamoxifen, GnRH agonists): Discuss with your oncologist or prescribing clinician before adding any agent. Low-dose venlafaxine (37.5 to 75 mg daily) has the best evidence among non-hormonal options for tamoxifen-related hot flashes in premenopausal women and does not interact with NK3 pathways.

If you have postpartum hot flashes: Wait and watch for 8 to 12 weeks. Most resolve spontaneously as prolactin levels adjust. Ensure you are not hypothyroid, which is common postpartum.

If you have surgical menopause in your 20s and cannot use hormones: Fezolinetant becomes a reasonable conversation. Discuss the liver monitoring requirements, contraception needs if relevant, and the fact that it will not protect your bones or your cardiovascular system the way hormones would.

Talking to Your Clinician: Questions Worth Asking

Before any provider prescribes Veozah to you as a woman in your 20s, these questions are worth raising directly.

• What do you think is causing my hot flashes? Have we checked FSH, estradiol, AMH, TSH, and a complete metabolic panel?
• Am I technically menopausal by any clinical definition, or do I still have active ovarian function?
• If I have POI, why is fezolinetant being considered before hormone therapy?
• What contraception will I need during treatment, and how does that interact with any other medications I take?
• How will we monitor my liver function, and what are the stopping rules?
• What happens to my menstrual cycle or fertility if I take this drug for six months?

A clinician who takes those questions seriously, and gives you specific rather than vague answers, is the clinician you want managing this.